--- title: "DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286311130.md" datetime: "2026-05-13T20:17:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286311130.md) - [en](https://longbridge.com/en/news/286311130.md) - [zh-HK](https://longbridge.com/zh-HK/news/286311130.md) --- # DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.48. EBIT: As of FY2026 Q1, the actual value is USD -2.005 M. DERMATA THERAPEUTICS, INC. operates as a single segment focused on the development, branding, marketing, and commercialization of direct-to-consumer (DTC) skincare products . #### Segment Revenue The company has not generated any revenue since its inception . #### Operational Metrics - **Net Loss:** For the three months ended March 31, 2026, the net loss was -$1,847,706, an improvement from -$2,303,587 for the same period in 2025 . - **Total Operating Expenses:** Total operating expenses decreased by -$413,421, from $2,339,803 for the three months ended March 31, 2025, to $1,926,382 for the three months ended March 31, 2026 . - **Research and Development (R&D) Expenses:** R&D expenses decreased by -$897,417, from $1,281,141 in the first quarter of 2025 to $383,724 in the first quarter of 2026 . This reduction was primarily due to a -$0.7 million decrease in clinical expenses from the completed XYNGARI™ STAR-1 acne study, a -$0.1 million decrease in chemistry, manufacturing, and controls (CMC) and non-clinical expenses, and a -$0.1 million decrease in personnel expenses . - **Selling, General and Administrative (SG&A) Expenses:** SG&A expenses increased by approximately $0.5 million, from $1,058,662 in the first quarter of 2025 to $1,542,658 in the first quarter of 2026 . This increase was mainly driven by $0.2 million in marketing expenses, $0.2 million in increased audit fees, and $0.1 million in increased legal fees . - **Loss from Operations:** Loss from operations was -$1,926,382 for Q1 2026, compared to -$2,339,803 for Q1 2025 . - **Interest Income:** Interest income increased by $42,460, reaching $78,676 in Q1 2026 from $36,216 in Q1 2025, due to increased cash balances from financing proceeds and interest from Employee Retention Tax Credit payments . - **Stock-Based Compensation:** Total stock-based compensation expense was $43,278 in Q1 2026, up from $37,189 in Q1 2025 . #### Cash Flow - **Net Cash Used in Operating Activities:** The company used -$2,479,718 in cash for operating activities in Q1 2026, compared to -$1,934,066 in Q1 2025 . The Q1 2026 figure was influenced by a net loss of -$1.8 million, increases in prepaid and other current assets and inventory (each $0.1 million), and decreases in accounts payable and accrued liabilities (approximately $0.5 million) . - **Net Cash Provided by Financing Activities:** Financing activities provided $1,903,022 in Q1 2026, primarily from $2.0 million in net proceeds from At The Market (ATM) sales, partially offset by -$0.1 million in issuance-related costs . In Q1 2025, financing activities provided $8,491,764, mainly from the January 2025 PIPE financing ($2.3 million net proceeds) and the March 2025 Inducement financing ($6.2 million net proceeds) . - **Cash and Cash Equivalents:** As of March 31, 2026, cash and cash equivalents totaled $6,945,282 . #### Unique Metrics - **Inventory:** Inventory, consisting of raw materials for Tome skincare products, was $93,091 as of March 31, 2026, compared to $0 as of December 31, 2025 . #### Future Outlook and Strategy DERMATA THERAPEUTICS, INC. made a strategic shift in September 2025 to focus on developing and distributing DTC and B2B skincare products, aiming for faster commercialization, reduced regulatory burden, and decreased development expenses . The company plans to launch its first cosmetic product, the Tome skincare Foundational Treatment, in mid-2026 and intends to develop additional skincare products, leveraging its Bioneedle platform for broad dermatologic and aesthetic applications . The company anticipates incurring further net losses and increased marketing expenses, necessitating additional capital beyond its current cash and cash equivalents, which are projected to fund operations into the first quarter of 2027 . ### Related Stocks - [DRMAW.US](https://longbridge.com/en/quote/DRMAW.US.md) ## Related News & Research - [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md) - [Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 | DRMA Stock News](https://longbridge.com/en/news/280689839.md) - [Ta Yang exits loss-making UK unit but keeps London foothold via asset swap](https://longbridge.com/en/news/286588935.md) - [What's Going On With eBay Stock Tuesday?](https://longbridge.com/en/news/286091849.md) - [HPE to Present Live Audio Webcast of Fiscal 2026 Second Quarter Earnings Conference Call | HPE Stock News](https://longbridge.com/en/news/285935495.md)